Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder (NCT04276883) | Clinical Trial Compass
CompletedPhase 3
Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder
United States380 participantsStarted 2020-02-24
Plain-language summary
This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in bipolar disorder. The BXCL501-302 study is designed to characterize the efficacy, safety and tolerability of BXCL501 (sublingual film formulation of DEX, HCl) in agitation associated with bipolar disorder.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male and female patients between the ages of 18 to 75 years, inclusive.
✓. Patients who have met DSM-5 criteria for bipolar I or II disorder.
✓. Patients who are judged to be clinically agitated at Screening and Baseline with a total score of ≥ 14 on the 5 items (poor impulse control, tension, hostility, uncooperativeness, and excitement) comprising the PANSS Excited Component (PEC).
✓. Patients who have a score of ≥ 4 on at least 1 of the 5 items on the PEC at Baseline.
✓. Patients who read, understand and provide written informed consent.
✓. Patients who are in good general health prior to study participation as determined by a detailed medical history, physical examination, 12-lead ECG with rhythm strip, blood chemistry profile, hematology, urinalysis, and in the opinion of the Principal Investigator.
✓. Participants who agree to use a medically acceptable and effective birth control method
Exclusion criteria
✕. Patients with agitation caused by acute intoxication, including positive identification of alcohol by breathalyzer or drugs of abuse (with the exception of THC) during urine screening.
✕. Use of benzodiazepines or other hypnotics or oral or short-acting intramuscular antipsychotic drugs in the 4 hours before study treatment.
✕. Treatment with alpha-1 noradrenergic blockers (terazosin, doxazosin, tamsulosin, alfuzosin, or prazosin) or other prohibited medications.
What they're measuring
1
Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score
✕. Patients who are judged to be at significant risk of suicide.
✕. Female patients who have a positive pregnancy test at screening or are breastfeeding.
✕. Patients who have hydrocephalus, seizure disorder, or history of significant head trauma, stroke, transient ischemic attack, subarachnoid bleeding, brain tumor, encephalopathy, meningitis, Parkinson's disease or focal neurological findings.
✕. History of syncope or other syncopal attacks, current evidence of hypovolemia, orthostatic hypotension.
✕. Patients with laboratory or ECG abnormalities considered clinically significant by the investigator.